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Abstract
Elevated rates of reinfection tuberculosis in various hyperendemic regions have been
reported and, in particular, it has been shown that in a high-incidence setting near Cape
Town, South Africa, the rate of reinfection tuberculosis (TB) disease after cure of a previous
TB disease episode is about four times greater than the rate of first-time TB disease. It is not
known whether this elevated rate is caused by a high reinfection rate due, for instance, to
living circumstances, or a high rate of progress to disease specific to the patients, or both. In
order to address that question we analysed an extensive data set from clinics attended by
TB patients in the high-incidence setting near Cape Town, South Africa and found that, in
fact, the (average) rate of reinfection (as opposed to the rate of reinfection disease) after
cure of a previous TB disease episode is initially about 0.85 per annum. This rate diminishes
rapidly over time and after about ten years this rate is similar to the rate of infection in the
general population. Also, the rate of progress to disease after reinfection is initially high but
declines in subsequent years down to the figure typical for the general population. These
findings suggest that the first few months after cure of a TB disease episode form a critical
period for controlling reinfection disease in a hyperendemic setting and that monitoring
such cured patients could pre-empt a reinfection progressing to active disease.
Introduction
It is known that in high TB incidence settings the rate of recurrent TB disease is much higher
than the rate for first-time disease [1]. Many of these recurrent disease cases are due to relapse
but the remaining cases are reinfection cases as confirmed by fingerprint comparison between
the first episode and second episode. Indeed, it has been shown that, at least in one high
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incidence setting, the dominant cause of recurrent disease after the first year following cure is
reinfection [2]. In the same setting the rate of reinfection disease appears to be as high as four
times the rate of first-time infection (primary) disease [3]. High reinfection disease rates have
also been reported from China [4] and elsewhere [1].
It is not clear why the rate of reinfection disease can be elevated compared to the rate of pri-
mary disease. It may be speculated that people who have already experienced a primary disease
episode have just been unfortunate in finding themselves in a high risk socioeconomic environ-
ment possibly involving their workplace, school, club or transport situation, where other infec-
tious cases continue to be present [5, 6]. Otherwise it could be that they are innately
predisposed to progress to disease, possibly due to genetic risk factors [7, 8], lung damage or
immunological deficiency caused by the previous episode, and perhaps smoking and drug
abuse. It may be that a combination of these factors could be responsible. So a high rate of rein-
fection or a high rate of progress to disease or both could be responsible for the high rate of
reinfection disease. The relative importance of these factors is the subject of much debate [9,
10] since direct observation of either of these rates is difficult. We estimated these rates by ana-
lysing an extensive data set collected from clinics serving a high TB-incidence setting near
Cape Town, South Africa. The results of the statistical analysis were followed by a mathemati-
cal analysis that enabled the estimation of the average annual rate of reinfection and average
annual rate of progress to disease corresponding to increasing time periods after cure. Our
results show clearly that it is the very high average annual rate of reinfection immediately after
cure that drives the high rate of reinfection disease. The rate of progress to disease is also ele-
vated but to only a modest extent. We show that both these rates decrease over time.
Methods
We estimate the annual rate of reinfection after cure of a previous first-time TB disease episode
and also the rate of progression to active disease after reinfection has occurred using data from
a particular hyperendemic community.
By ‘a reinfection disease episode’ we mean a disease episode resulting from a reinfection
event occurring after cure of a previous disease episode as confirmed by the two episodes hav-
ing different genotypes. By ‘cured’ we mean cured with bacteriological proof.
Data
We used data for the period 1993 to 2005 from the epidemiological field site of Ravensmead/
Uitsig, two adjacent hyperendemic urban communities of Cape Town.
These data had been collected and a subset of these data for the period 1993 to 1998 had
previously been used by the authors GVDS, RW and PvH in the published paper 3 in the refer-
ences. Another, overlapping, subset of these data for the period 1996 to 2008 had previously
also been used by the authors GVDS and PvH in the published paper 2 in the references. These
three different subsets were used as they represented the patient records that had been pro-
cessed and which were available at the time the respective studies had commenced. All geno-
type work was done by these authors and placed in their own databank. None of the authors of
this paper know the identity of the patients whose data was used. The patient information was
anonymised by independent persons and these authors have no access to any information that
can identify any person. The study was approved by SUN IRB (Stell Univ INst Review Board).
The main conclusions from these previous investigations were that:
1. The rate of reinfection TB disease was about four times that of new TB disease [3].
Risk of TB Reinfection
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2. Overall, reinfection was the dominant cause of recurrent tuberculosis after treatment had
been completed [2].
For the present investigation we considered it necessary to take the following into account:
1. It is possible that the rate of reinfection or the ensuing rate of progression to disease may
vary depending on the number of previous TB disease episodes experienced by the patient
so we considered only first reinfection disease episodes i.e. reinfection disease episodes after
a cured first TB episode.
2. The rate of recurrent disease forms an upper bound for the rate of reinfection disease. A
recurrent disease with the same strain as a previous disease episode may be the outcome of a
reinfection event subsequent to the cure of the previous disease episode or it could just be a
relapse of the earlier disease episode. Since it is not possible to distinguish between these
two scenarios using the available data, we assumed conservatively, that a recurrent TB epi-
sode should be classified as a reinfection disease episode only if the genotypes for the two
episodes were different–otherwise we assumed the second to be a relapse case. The reinfec-
tion rate estimated based on this assumption is likely an underestimate of the true reinfec-
tion rate since it is possible that patients could be reinfected with a commonly circulating
strain or exposed to the same untreated index case.
3. We considered all patients who had documented first TB disease episodes that were cured
with bacteriologic proof. For these patients we obtained an estimate of the time interval
from the date of cure of the first disease episode to the date of the start of the recurrent TB
disease episode. In the dataset only the dates on which a patient was seen at the clinic were
documented. We therefore assumed that the date of cure is six months after commencement
of treatment for susceptible TB and eighteen months for multiple drug resistant TB. We
assumed that all TB cases for which resistance information was not sufficiently documented
were not multiple drug-resistant i.e. had a treatment period of 6 months. It should be noted
that since this assumption will result in an over-estimation of the time to reinfection disease
for some cases, it will cause an underestimation of the rate of reinfection.
4. The estimated date of the start of the recurrent disease episode was determined based on the
assumption that patients go to the clinic (and get diagnosed) as soon as symptoms appear,
which is in turn assumed to occur one month after the disease episode actually begins. It
may happen that a patient delays visiting a clinic so that his disease episode actually starts
earlier than our estimate: If this was in fact the case for some patients, our assumption
would contribute to under-estimation of the rate of reinfection disease.
5. Unfortunately fingerprint typing for both the first and the second disease episodes was not
available for all the patients whose first episode had been cured (with bacteriological proof).
It is reasonable to suppose that the cases where both episodes had been typed form a ran-
dom sample of this larger population (i.e. genotyping information is missing completely
at random). In reference [3] it is made clear that the patients with DNA fingerprints were
representative for those without so that the cases where fingerprints were missing do not
constitute a biased subset. We believe therefore that we may assume that fingerprints are
missing in an entirely random way resulting from, for example, administrative error or loss
of viability of specimens during transport from the clinics to the laboratories or just simple
laboratory failures. So for those patients missing typing data, we assume the same propor-
tion pDiff experienced reinfection disease as in the subgroup with typing data available for
both episodes. Since we believe this to be a reasonable assumption we will consider all cases
with a cured first TB episode instead of only the subset with genotyping data available for
Risk of TB Reinfection
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both episodes. In this manner we obtain a larger subset to analyse. We noted that the pro-
portion of the confirmed reinfection cases (where the first episode had been cured) com-
pared to all recurrent cases (after cure) is pDiff = 0.57. The risk of reinfection disease within a
period of time t after cure of a first disease episode is then calculated as 0.57 times the risk of
recurrent disease within a period of time t after cure of a first disease episode.
Statistical Analysis
We considered all patients for whom there was a documented first TB disease episode that was
cured with bacteriologic proof. For these patients we obtained an estimate of the time interval
from the date of cure of the first disease episode to the date of infection with the recurrent TB
infection. In the data set only the dates on which a patient was seen at the clinic were docu-
mented. So we estimated the date of infection for the recurrent episode on the assumption that
patients go to the clinic (and get diagnosed) as soon as symptoms appear. This is assumed to
occur 1 month after infection. Treatment for multi-drug resistant TB (defined as resistant to at
least isoniazid and rifampicin) was assumed to be over an 18 month period while treatment of
susceptible TB was assumed to take 6 months. The time interval was then calculated from the
date of completion of the treatment until one month before diagnosis of the recurrent episode.
This over-estimates the interval since it is most likely patients report to a clinic much later than
one month after appearance of symptoms. Furthermore, again to be conservative, it was
assumed that all TB disease cases for which resistance information was not documented (or
sufficiently documented) were not multiple drug resistant and so had a treatment period of 6
months. For actual MDR cases this over-estimates the time to reinfection.
Survival analysis was performed on the time-to-event data. The survival function was esti-
mated using the product-limit estimator [11]. In the analysis individuals who experienced
recurrence after the cure of their first episode, were censored at the time of recurrence (mean-
ing that they were only considered to be at risk of reinfection until that time and only contrib-
uted to the analysis until that time), while those who did not experience relapse or reinfection
(as far as we know) prior to the 10th of October 2005 (the date of the last clinic visit in the data
set) were censored at this date. This type of censoring is called right censoring.
No information regarding for example migration or death was available after treatment
ended for a patient. It was therefore necessary to make the assumption that if an individual did
not return to the clinic, they survived recurrent TB disease as well as death. This assumption
will most likely result yet again in an underestimate of the rate of reinfection. The survival anal-
ysis was performed using the R programming language and built in functions of an R package
called ‘survival’. These functions correctly account for right censoring.
The pointwise confidence intervals for the Kaplan Meier curve for the survival of recurrent
TB disease are derived from the confidence interval of the log hazard [12].
The confidence limits for the risk of reinfection disease can be obtained as follows. Since the
risk of a recurrent TB disease episode within time t after cure is 1 minus the probability of sur-
viving a recurrent TB disease episode for time t, the upper confidence limit of the risk of a
recurrent disease episode within time t is 1 minus the lower confidence limit of the correspond-
ing survival probability. Similarly for the lower confidence limit of the risk of a recurrent. The
confidence limits for the risk of a reinfection disease episode (i.e. recurrent TB disease with a
genotype different from that of the first) are pDiff times the corresponding confidence limits of
the risk of a recurrent TB disease episode.
It is this risk of reinfection disease over increasing time periods post cure of first disease epi-
sode that is examined in the next section, Mathematical Analysis, in order to investigate the
annual rate of reinfection and the annual rate of progress to disease after reinfection.
Risk of TB Reinfection
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Mathematical Analysis
Here we present a summary of the method used to estimate the annual rate of reinfection and
the annual rate of progress to disease.
We let λ1 and λ2 denote the annual rate of reinfection and the annual rate of progression to
active disease after reinfection, respectively.
The probability, D, of becoming reinfected and then progressing to disease within T years
after cure of a previous infection is given by
D ¼ R T
0
el1tl1ð1 el2ðTtÞÞdt
¼ el1T þ l1
l1  l2
½el1T  el2T  þ 1
¼ 1
l1  l2
½l2el1T  l1 el2T  þ 1 ð1Þ
We observe that this shows that the probability, D, increases from 0 at time T = 0. Fig 1
shows D for some values of λ1 and λ2.
We now use the data regarding this probability to estimate λ1 and λ2.
We proceed from Eq (1) by calculating dD
dT
¼ l1l2l1l2 el1T  el2T½  and ﬁnding the second-
order approximation (valid if λiT 1):
dD
dT
 l1l2T 1
1
2
l1 þ l2ð ÞT
 
ð2Þ
Let R ¼ dDdTðT2ÞdD
dTðT1Þ
. Then (2) shows
l1l2 ¼
dD
dT
ðT1Þ
T1 ½1 12 ðl1 þ l2ÞT1
¼ a; say;
and l1 þ l2ð Þ ¼ 2ðRT1T2Þ½RT12T22  ¼ b, say.
Hence li ¼ b
ﬃﬃﬃﬃﬃﬃﬃﬃ
b24a
p
2
It cannot be determined at this stage whether λ1 is given by
bþ
ﬃﬃﬃﬃﬃﬃﬃﬃ
b24a
p
2
or by b
ﬃﬃﬃﬃﬃﬃﬃﬃ
b24a
p
2
.
Results
The five points made in the Methods section were taken into account when dealing with the
data and the way these points determined which cases should be covered by our study (from
the period 1993 to 2005) is best explained in Fig 2 which shows the number of patients in each
of several categories of interest. Our analysis was applied to the 943 patients for whom the first
disease episode was cured and the results are shown in Table 1.
For the data covered by our analysis, pDiff (which was defined in the Methods section) is
equal to 0.57 (33/57—Table 1). We can therefore expect that about 93 of the 163 patients
(0.57163 = 93) with a cured first episode and an observed second episode (see Fig 2) experi-
enced that second episode as a result of reinfection. This represents about 10% of the 943
patients with a cured first disease episode. Thus reinfection disease constitutes a significant
proportion of the case load.
The risk of reinfection disease as determined from the data and recorded in Table 1 increases
as a function of time from cure of the first disease episode and is shown graphically in Fig 3.
Risk of TB Reinfection
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The Kaplan Meyer survival plot is shown in Fig 4.
Comparison of the graphs in Fig 3 with the theoretical graphs in Fig 1 shows that the rate of
reinfection and the rate of progress to disease cannot be constant. Rather, it appears that in fact
the rates are high initially and decrease during the subsequent years.
In Fig 3 a polynomial trend line is fitted to the graph of the probability of reinfection disease.
This polynomial is differentiated to obtain the gradient to the probability graph for various
times after cure. This is done for the Upper and Lower confidence interval bounds as well.
This enables the estimation, using the formulae in Methods, of quantities l1 and l2 (Table 2),
these being candidates for λ1 and λ2. (Recall that the formulae derived in the Methods section
do not distinguish between the rate of reinfection and the rate of progress to disease). l1 and l2
are plotted in Fig 5. Fig 5 shows that l1 and l2 decrease over time with l2 tending towards a
value typical for the generally accepted value of the rate of progress to disease. We deduce then
that l1 represents the annual rate of reinfection after cure i.e. λ1.
Recall that the derivation of the formulae assumes that λ1 and λ2 are constant over time.
Application of these formulae will therefore yield estimates for average values of λ1 and λ2 over
the selected time periods. In particular, the values found for larger times T will be inflated
because they are affected by contributions from earlier years when the values are high. Despite
these limitations, Fig 5 shows that initially the values are very high with the average value of λ1
about 0.85 during the first year after cure. These values drop off very quickly. The size of the
Fig 1. For Series 1 through 3 the values of λ1 and λ2 are respectively (0.05; 0.025), (0.3; 0.025) and (0.025; 0.01).
doi:10.1371/journal.pone.0144487.g001
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estimate of the average annual rate of reinfection over 10 years after cure (0.114 per annum)
suggests that after about 10 years the rate of reinfection is similar to the rate of (first) infection
for the population in general.
Conclusion
It has been established elsewhere that in hyperendemic settings reinfection is the major cause
of recurrent TB disease. We found in the present study pertaining to the specific settings identi-
fied that it can be expected that approximately 57% of patients who were cured of a first epi-
sode and who experienced a recurrent episode, experienced reinfection as opposed to relapse.
These reinfection cases constitute a significant proportion (at least 10%) of all cases where
the first episode had been cured. Moreover we also note that 43% of the patients who were
cured with proof had a second episode with the same strain as the first. For the purposes of our
analysis we conservatively regarded these as relapse cases but it is quite likely that such patients
had been reinfected by commonly circulating strains or even by the (untreated) people respon-
sible for infecting them the first time. In fact, we have previously found an association of spe-
cific Mtb strains with humans with a particular HLA type [13], and this could also explain
why, in a hyperendemic setting with a number of strains present in the environment, the strain
infecting the host the second time is often the same as the first, as this strain is the best “fit” for
Fig 2. A schematic showing the breakdown of the 3364 patients with a documented first TB disease episode.
doi:10.1371/journal.pone.0144487.g002
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that host. Since reinfection with the same strain was an exclusion criterion here, the estimated
rate of reinfection leading to disease is an underestimate.
Our study revealed that patients cured of a first disease episode were at great risk of becom-
ing reinfected during the initial months after cure. Initially the annual reinfection rate is about
0.85, (see the Appendix for a very simple explanation of why this is actually a perfectly reason-
able value for the reinfection rate) but the rate drops off very rapidly during the subsequent
two to three years and continues to drop so that by about ten years since cure the rate has a
value typical of that for the population generally. It may be hypothesised that these patients
continued in a high risk environment after cure but such high risk conditions diminish over
time for them as, for example, they move to different employment or the infectious people to
whom they had been exposed become cured themselves. But we also know that human genetic
susceptibility plays a significant role in determining which of the latently or newly infected
hosts progress to active disease [14], and we may expect these hosts to have repeated episodes
of disease in a hyperendemic area. We hypothesize that different allelic frequencies in genes
that are crucial at a number of stages in the immune defence against Mtb will impact the host
resistance to this infection and its progression. Within an admixed population such as that
investigated here, there will be a wide variety of susceptibility alleles, some derived from differ-
ent ancestral input [15, 16, 17] and others representing normal variation in any population [18,
19, 20, 21]. Resistance to TB may encompass resistance to infection, or resistance to progres-
sion of disease, and our linkage studies in this community show that two separate loci are
involved [22], and we postulated that patients who maintain a zero measure for skin test
Fig 3. Themean risk of reinfection disease manifesting a given number of years after cure of a prior cured disease episode is shown together with
confidence intervals. Trend lines are fitted and these are used to estimate the gradients of the risk graphs. The trendline for the mean risk of reinfection
disease only is shown and its parameters are displayed.
doi:10.1371/journal.pone.0144487.g003
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positivity, are inherently resistant. This cohort would by definition not have the first episode of
TB, and would therefore not be included in the present study. Those who are most susceptible
will succumb rapidly again after the first infection, while as time passes and this susceptible
cohort is “removed” from the pool of patients recovering from TB, the apparent rate of reinfec-
tion will go down. This mechanism is supported by Rodrigues et al [23] and Gomes et al, [24],
Fig 4. The Kaplan Meyer survival plot from Table 1.
doi:10.1371/journal.pone.0144487.g004
Table 2. Rate of reinfection disease, with confidence intervals for various times after cure.
CI Upper Rate CI Lower
Time l1 l2 l1 l2 l1 l2
0.5 0.962 0.079 0.966 0.068 0.969 0.057
1.5 0.494 0.058 0.493 0.051 0.492 0.043
2.5 0.334 0.051 0.333 0.046 0.333 0.040
3.5 0.256 0.046 0.253 0.042 0.256 0.037
4.5 0.209 0.041 0.207 0.038 0.212 0.034
5.5 0.179 0.037 0.177 0.035 0.186 0.031
6.5 0.157 0.033 0.156 0.032 0.169 0.028
7.5 0.141 0.029 0.141 0.029 0.158 0.025
8.5 0.128 0.026 0.130 0.025 0.152 0.022
9.5 0.116 0.022 0.121 0.023 0.148 0.019
10.5 0.105 0.019 0.114 0.020 0.147 0.017
doi:10.1371/journal.pone.0144487.t002
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as fitting the data better than the hypothesis that infection increases susceptibility to
reinfection.
However, we need to consider another possible explanation for the high rate of reinfection
shortly after cure; namely, that the patient’s immune system remains compromised for a signif-
icant period after bacterial cure, as a result of the disease episode. Cytokine levels and networks
may remain disrupted due to their slow recovery after an episode of TB. In patients cured of an
episode of TB, the levels of IFN-γ immunoreactivity remain suppressed at the end of therapy
[25] and for at least 12 months after the start of therapy [26]. IFN-γ is important in the
TH1-type cytokine response, and while a depressed level of IFN-γ activity may point to genetic
susceptibility in some patients, the levels at 18 months have recovered to control levels, indicat-
ing the time dependence of the effect [26]. The ratios of other cytokine such as TNF-α/IL-10
were significantly increased in TB patients before, during, and also at the end of treatment
compared to those of control subjects [25]. Pathogenic mycobacteria can subvert the autop-
hagy/apoptotic pathways, and a number of signalling cascades, and the extent and duration of
these effects is not known.
The delicate balance between the survival of the pathogen and the success of the host
defence system could be tipped in favour of disease success in the months after an infection, for
a combination of all the above reasons [27] and this, in combination with the genetic suscepti-
bility previously discussed, manifests as an early increase in disease after cure.
The first episode of TB has already served to identify those infected persons that are likely to
progress to disease, and the public health benefit of monitoring this subset of the population
for a short period to prevent the even smaller subset which may be the most genetically suscep-
tible and is at increased risk of a second episode of disease, seems well worth the effort.
Whether such monitoring should be implemented and for how long such monitoring
should continue would be best determined by a cost-benefit analysis compared to other types
of control measures.
Fig 5. The confidence intervals for l2 are not plotted since they are too small to be visible.
doi:10.1371/journal.pone.0144487.g005
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This study does not provide definitive answers as to why the rate of actual reinfection soon
after cure is so high. However, should monitoring take place, it is likely that the reason a patient
has become reinfected so quickly could become evident. This in itself could suggest more effi-
cient measures.
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